IN CONVERSATION WITH SANDEEP K. RATHOD
Our Partner, Clarence Anthony, speaks with Sandeep K. Rathod, Global General Counsel & Head of Compliance, at Piramal Pharma Limited, about his M&A experience in pharmaceuticals and healthcare, and what one can expect in the next couple of years in this space.
The discussion revolves around identifying legal risks in pharma M&A deals and the structuring of in-house and external counsel teams to complement each other’s expertise when getting the deal done. They talk about IP issues, and confidentiality and data privacy, in the context of M&A deals in the pharmaceutical sector.
Finally, they delve into the outlook for the pharma sector in the next two years and elaborate on some emerging trends such as an increased focus on medical devices, the possibility of PE exits, and potential IPOs.
Profile
Sandeep K. Rathod
Sandeep K. Rathod is the Global General Counsel & Head of Compliance at Piramal Pharma Limited (PPL). He has more than two decades of experience as an in-house lawyer and has worked extensively in the pharmaceuticals and healthcare space on legal and compliance related aspects, including contracts, litigation, deals, and strategic advisory.
He has a Master’s degree in Law from the University of Mumbai as well as the University of Pittsburgh, School of Law. Sandeep’s strength lies in identifying, mitigating, and managing legal risk, and he plays an important role in executing corporate transactions, advising on complex intellectual property aspects, and managing the compliance program at PPL.
